Adaptive immunity-related gene expression profile is correlated with clinical phenotype in patients with acute myeloid leukemia

Abstract

Background: Acute myeloid leukemia (AML) is a common and lethal hematopoietic malignancy that is highly dependent on the immune microenvironment. However, light has yet to be shed on the landscape of adaptive immunity-related genes. This work aimed to uncover the novel molecular events in AML and potential therapeutic strategies for AML treatment.Methods: For the current research, the transcriptional information of 732 genes that participate in adaptive immunity was collected from 173 patients with AML, and the patients were grouped into different cohorts based on the different expression patterns. The correlations between gene expression and clinical characteristics, including prognosis, were studied.Results: According to the notably different expressions of adaptive immunity-related genes, the 173 patients were divided into 2 clusters and 3 subclusters. No significant differences in overall survival (OS) or progression-free survival (PFS) were detected between the clusters or subclusters. There were obvious discrepancies found in age, peripheral blood (PB) blast percentage, and French-American-British (FAB) classification between each cluster or subcluster. The patients in cluster 1 were older and more of them had M5 type; the patients in cluster 2 were younger and more of them had M2 type. Further, 81 genes were significantly correlated with age and 101 genes were significantly correlated with PB blast percentage.Comparison of the prognosis between each FAB type revealed that patients with M3 type displayed the most favorable OS and PFS. Among the differentially expressed genes (DEGs), CLEC2B expression was much lower in M2 patients than in patients with other types (P<0.001), and its high expression indicated a worse outcome (12.4 vs. 46.5 months of OS).Conclusions: This study has uncovered the expression profile of adaptive immunity-related genes in AML. The different gene expression patterns are not associated with survival, but are significantly correlated the FAB types. CLEC2B expression is low in patients with M2 type and is negatively correlated with prognosis, thus revealing a potential therapeutic target for AML.

An integrative analysis to reveal that CLEC2B and ferroptosis may bridge the gap between psoriatic arthritis and cancer development

“…Based on aforementioned results, we further explored the function of CELC2B in pan-cancer. In previous studies, CLEC2B has been identified as a marker for a variety of cancers, including clear cell renal cell carcinoma, melanoma, and pancreatic adenocarcinoma 45 , 46 . Similar to the findings of prior studies, this study found vital functions for CLEC2B in numerous cancers, including changes in expression, correlation with prognosis, infiltration of multiple immune cells and even immune checkpoints in multiple cancer types.…”

MiRNA-142-3P and FUS can be Sponged by Long Noncoding RNA DUBR to Promote Cell Proliferation in Acute Myeloid Leukemia

“…Its incidence rate is approximately 1.62/1 million worldwide and increases with age (Döhner et al, 2015). The French-American and British (FAB) classification of acute myeloid leukemia (AML) is based on the recognition of granulocytic (M1, M2, and M3), granulocytic-monocytic (M4), monocytic (M5a, M5b), erythroid (M6), and megakaryocytic (M7) types of cells (Chen et al, 2021). This classification has been widely accepted due to its reproducibility and true morphological correlation.…”